AARTIPHARM
₹790.45-65.75 (-7.68%)
Quarterly ResultsProfit & LossBalance SheetCash Flow
Key Insights
POSITIVE
- Net sales increased to ₹563.78 crore in Q1 2025, reflecting strong demand compared to previous quarters.
- Operating profit and margin improved significantly to 20.62%, indicating better cost management and efficiency.
- Net profit reached ₹88.34 crore, up by 19% from the prior quarter, demonstrating healthy growth potential.
NEGATIVE
- Company experienced a cash flow shortfall with a 10% decrease this year [Dummy Data]
- Company’s strategic partnerships have yet to generate expected growth. [Dummy Data]
- Company’s EBITDA shrank at a CAGR of -8% over the past 3 years. [Dummy Data]
Quarterly Results Data
| Field | Trend | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 439.80 | 448.69 | 505.77 | 555.49 | 458.03 | 537.78 | 563.78 | 386.19 | |
| Expenses | 373.84 | 376.26 | 412.05 | 484.03 | 390.74 | 442.18 | 447.55 | 320.54 | |
| Operating Profit | 65.96 | 72.43 | 93.72 | 71.46 | 67.29 | 95.60 | 116.23 | 65.65 | |
| Other Income | 0.98 | 1.39 | 2.03 | 2.22 | 4.48 | 5.03 | -1.61 | 1.60 | |
| Interest | 3.89 | 4.48 | 4.68 | 4.83 | 5.51 | 9.97 | 6.58 | 6.79 | |
| Depreciation | 18.14 | 18.77 | 19.12 | 20.17 | 20.88 | 23.04 | 22.82 | 22.79 | |
| Profit Before Tax | 66.94 | 73.82 | 95.75 | 73.68 | 71.77 | 100.63 | 114.62 | 65.45 | |
| Tax | 15.14 | 21.06 | 30.50 | 18.22 | 17.14 | 26.64 | 26.28 | 15.95 | |
| Net Profit | 51.80 | 52.76 | 65.25 | 55.45 | 54.62 | 73.99 | 88.34 | 49.50 | |
| EPS in Rs | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 |